Apyx Medical Corp. (APYX) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Apyx Medical Corporation Reports First Quarter 2019 Financial Results and Updates Fiscal Year 2019 Outlook
May 8, 2019 4:05 PM EDTAdvanced Energy Sales of $4.4 million in Q1, up 66% year-over-year
CLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx Medical Corporation (NASDAQ: APYX) (the Company), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion Cosmetic Technology brand in the cosmetic surgery market, today reported financial results for its first quarter ended March31, 2019.
First Quarter 2019 Financial Summary:
Total Q1 revenue from continuing operations of $5.8 million, up 71% year-over-year. Advanced Energy revenue of $4.4 million, up 66% year-over-year.... More